Breaks Categories: News

TuesdayDec 10, 2024 12:33 pm

BioMedNewsBreaks — Clene Inc. (NASDAQ: CLNN) Advances CNM-Au8 in ALS with FDA Guidance on Accelerated Approval Pathway

Clene (NASDAQ: CLNN) received FDA guidance on leveraging data from its ongoing expanded access programs (“EAPs”) to support an accelerated approval application for CNM-Au8, its treatment for ALS. The FDA recommended using neurofilament light chain (“NfL”) biomarker analyses to substantiate the drug’s efficacy. Clene plans to submit additional data in mid-2025, alongside commencing the Phase 3 RESTORE-ALS trial. Clinical findings presented at an FDA meeting highlighted CNM-Au8’s significant survival benefits and benign safety profile, underscoring its potential as a transformative ALS therapy. Clene remains committed to addressing the urgent unmet needs of ALS patients. To view the full press release, visit https://ibn.fm/xFrwd…

Continue Reading

TuesdayDec 10, 2024 10:44 am

BioMedNewsBreaks — NextPlat Corp (NASDAQ: NXPL) Expands e-Commerce Presence in China Through JD.com Partnership

  NextPlat (NASDAQ: NXPL, NXPLW)  has secured vendor approval from JD.com, China’s largest self-operated e-Commerce retailer, to sell OPKO Health Europe’s branded health, wellness, and veterinary products. Under an exclusive agreement with OPKO Health Europe, NextPlat will begin listing nutraceutical products for bone and joint health, nutrition, and immunity on JD.com in early 2025, with plans to expand offerings to include innovative veterinary care products pending regulatory clearance. Leveraging JD.com’s platform, which serves over 560 million annual users, this initiative aligns with the growing demand for premium healthcare products in China, where the nutraceutical market is projected to reach $100…

Continue Reading

MondayDec 09, 2024 1:34 pm

BioMedNewsBreaks — NextPlat Corp (NASDAQ: NXPL) Projects Over 70% Revenue Growth for 2024, Driven by Key Business Segments

NextPlat (NASDAQ: NXPL, NXPLW)  anticipates reporting approximately $63 million in annual revenue for 2024, reflecting a more than 70% increase from fiscal 2023 results, subject to final accounting and auditing. The significant growth is attributed to strong performance in satellite connectivity products, high-margin recurring airtime revenue, and contributions from the healthcare business. The company plans to file its 2024 annual report by March 31, 2025, and host an earnings conference call with investors. To view the full press release, visit: https://ibn.fm/CeHlA About NextPlat Corp NextPlat is a global e-commerce platform company created to capitalize on multiple high-growth sectors and markets…

Continue Reading

ThursdayDec 05, 2024 2:57 pm

BioMedNewsBreaks — Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Announces Strategic Board Appointment

Scinai Immunotherapeutics (NASDAQ: SCNI), a biopharmaceutical company specializing in the development of inflammation and immunology (“I&I”) biological products and offering CDMO services through its Scinai Bioservices unit, today announced the appointment of Prof. Michael Schön to its Scientific Advisory Board (“SAB”). Recognized with numerous awards for his groundbreaking research on immune reactions in inflammation, Prof. Michael Schön is a distinguished professor and director of the Department of Dermatology, Venereology and Allergology at the University Medical Center Göttingen. He also serves as vice dean and deputy director for research and teaching and is the former director of the Lower Saxony Institute…

Continue Reading

ThursdayDec 05, 2024 2:47 pm

BioMedNewsBreaks — Branded Legacy Inc. (BLEG) Reaffirms Commitment to Growth and Innovation in Biotech, Wellness Sectors

Branded Legacy (OTC: BLEG) today announced updates as it confronts recent challenges and charts a focused path forward. In the announcement, the company reaffirmed its commitment to the biotech and wellness sectors, with its primary focus on expanding its wholly owned subsidiary, Sycamore BioPharma. “These challenges have only strengthened our resolve,” stated Branded Legacy CEO Dave Oswald. “While the actions of former employees have created significant hurdles, our commitment to growth and innovation remains unwavering. By focusing on our more successful subsidiaries and securing the necessary funding to expand, we are poised to recover and achieve even greater success in…

Continue Reading

ThursdayDec 05, 2024 11:00 am

BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) to Host Virtual Analyst & Investor Day on December 11

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company developing treatments for brain and central nervous system cancers, will host a Virtual Analyst & Investor Day on December 11 from 11:30 a.m. to 1 p.m. ET. The event will feature presentations by the company’s leadership team, including CEO John Climaco, Chief Medical Officer Dr. Sandra Silberman, and VP of Clinical Operations Zena Muzyczenko, alongside key opinion leaders Dr. Michael Weller, Dr. Samuel Goldlust, and Dr. Erin Dunbar. Discussions will focus on glioblastoma multiforme (“GBM”), updates on the clinical development of Berubicin, and regulatory strategies for the company’s second asset, TPI 287. A…

Continue Reading

ThursdayDec 05, 2024 9:10 am

BioMedNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) CEO Highlights Innovations in Neurodegenerative Drug Development on Today’s Marketplace

Annovis Bio (NYSE: ANVS), a leader in developing treatments for neurodegenerative diseases, was recently featured on Today’s Marketplace in an exclusive interview with Dr. Maria Maccecchini, Founder, President, and CEO. Dr. Maccecchini detailed Annovis Bio’s groundbreaking drug development targeting toxic proteins responsible for nerve cell damage in Alzheimer’s and Parkinson’s, as well as the company’s next-phase clinical trials. Emphasizing the broader impact of these diseases on caregivers as well as patients, Dr. Maccecchini shared insights into the meaningful progress Annovis Bio is making. The Today’s Marketplace feature continues to spotlight Annovis Bio’s leadership in addressing critical healthcare challenges, reinforcing its…

Continue Reading

WednesdayDec 04, 2024 3:41 pm

BioMedNewsBreaks — Annovis Bio Inc. (NYSE: ANVS) CEO Shares Insight on Breakthrough Drug Showing Promise for Neurodegenerative Diseases

Annovis Bio (NYSE: ANVS) was featured in an interview with Today's Marketplace (“TMP”). The company’s Founder, President and CEO, Maria Maccecchini, PHD, and Scott Shipman, MD, MPH, Executive Director for Creighton University's Institute for Population Health, joined host Jane King to discuss clinical trials of a new drug that is showing promise for the treatment of neurodegenerative diseases like Alzheimer's (“AD”) and Parkinson's (“PD”) and their impact on population health. "We have over 7 million people with neurodegeneration in the United States, and it is a huge problem. We think of the patients, but we should also think of the…

Continue Reading

TuesdayDec 03, 2024 3:30 pm

BioMedNewsBreaks — BioAdaptives Inc. (BDPT) Announces One-for-One Stock Dividend

BioAdaptives (OTC: BDPT) today announced that its board of directors approved a dividend to all common stockholders. According to the announcement, stockholders will receive matching shares for all of their owned shares on the record date. “This dividend is designed to acknowledge your steadfast belief in our vision and to reward you for standing by us as valued stakeholders,” said BDPT CEO James Keener. “This special dividend aligns with our dedication to enhancing shareholder value while reinforcing our focus on long-term growth and success. The additional shares you will receive signify our shared optimism for the future and our determination…

Continue Reading

WednesdayNov 27, 2024 9:56 am

BioMedNewsBreaks — Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Welcomes Dr. Jonathan Sadeh to Scientific Advisory Board

Scinai Immunotherapeutics (NASDAQ: SCNI) has appointed Dr. Jonathan Sadeh to its Scientific Advisory Board, where he will support the advancement of the company’s IL-17 program and VHH antibody pipeline. Dr. Sadeh brings over 20 years of drug development experience, including senior leadership roles at Bristol-Myers Squibb, where he led programs in immunology, cardiovascular, and neuroscience, and was instrumental in the approval of Sotyktu for psoriasis. With a background in pulmonary and critical care from Harvard Medical School and a focus on innovative therapies addressing unmet medical needs, Dr. Sadeh expressed enthusiasm for Scinai’s bio-better approach and collaborations with institutions like…

Continue Reading